The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

PubWeight™: 3.17‹?› | Rank: Top 1%

🔗 View Article (PMC 2715080)

Published in J Exp Med on June 15, 2009

Authors

Cameron S Brandt1, Myriam Baratin, Eugene C Yi, Jacob Kennedy, Zeren Gao, Brian Fox, Betty Haldeman, Craig D Ostrander, Tomonori Kaifu, Christian Chabannon, Alessandro Moretta, Robert West, Wenfeng Xu, Eric Vivier, Steven D Levin

Author Affiliations

1: Molecular and Cell Based Discovery, ZymoGenetics Inc., Seattle, WA 98102, USA.

Articles citing this

(truncated to the top 100)

Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68

Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72

Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood (2009) 3.46

Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43

Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol (2013) 3.38

Natural killer cell lytic granule secretion occurs through a pervasive actin network at the immune synapse. PLoS Biol (2011) 1.92

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.77

The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment. Gut (2013) 1.60

Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. Cell Host Microbe (2015) 1.58

Natural killer cell biology: an update and future directions. J Allergy Clin Immunol (2013) 1.56

Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54

B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52

The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol (2013) 1.38

Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 1.37

Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol (2011) 1.36

Mechanisms and functions for the duration of intercellular contacts made by lymphocytes. Nat Rev Immunol (2009) 1.36

Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther (2009) 1.32

Cell surface signaling molecules in the control of immune responses: a tide model. Immunity (2011) 1.32

Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood (2010) 1.32

The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci U S A (2010) 1.28

Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol (2014) 1.27

Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood (2013) 1.22

Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med (2010) 1.20

The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther (2013) 1.16

Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol (2013) 1.13

Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica (2014) 1.12

Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC. Immunogenetics (2012) 1.12

TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat Cell Biol (2013) 1.12

Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med (2011) 1.11

Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11

Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol (2011) 1.10

Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol (2013) 1.10

Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol (2015) 1.10

Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions. Int Immunol (2012) 1.08

Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol (2014) 1.07

B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS One (2013) 1.05

NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04

TLR/NCR/KIR: Which One to Use and When? Front Immunol (2014) 1.03

Recognition strategies of group 3 innate lymphoid cells. Front Immunol (2014) 1.03

Killing of avian and Swine influenza virus by natural killer cells. J Virol (2010) 1.03

Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol (2011) 1.02

A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst (2014) 1.02

The phylogenetic origins of natural killer receptors and recognition: relationships, possibilities, and realities. Immunogenetics (2010) 1.01

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol (2014) 1.00

Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect (2012) 0.99

Coordinated regulation of NK receptor expression in the maturing human immune system. J Immunol (2014) 0.99

The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. J Biol Chem (2012) 0.98

Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother (2011) 0.98

The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw (2014) 0.96

Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 0.95

An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol (2012) 0.95

Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS One (2012) 0.94

Cutting Edge: identification of neutrophil PGLYRP1 as a ligand for TREM-1. J Immunol (2015) 0.94

Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol (2012) 0.94

Natural killer cells: role in local tumor growth and metastasis. Biologics (2012) 0.94

Structural basis for recognition of cellular and viral ligands by NK cell receptors. Front Immunol (2014) 0.94

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res (2014) 0.94

Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood (2014) 0.94

Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93

Natural killer cells: from basic research to treatments. Front Immunol (2011) 0.93

B7 family molecules as regulators of the maternal immune system in pregnancy. Am J Reprod Immunol (2010) 0.93

Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma. PLoS Pathog (2012) 0.93

Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology (2013) 0.92

Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem (2014) 0.92

Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci U S A (2011) 0.92

Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res (2012) 0.91

NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun (2015) 0.90

Targeting the B7 family of co-stimulatory molecules: successes and challenges. BioDrugs (2013) 0.89

Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV. Front Immunol (2014) 0.89

Rapid NK cell differentiation in a population with near-universal human cytomegalovirus infection is attenuated by NKG2C deletions. Blood (2014) 0.89

Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87

B7-H6 expression in non-small cell lung cancers. Int J Clin Exp Pathol (2014) 0.87

Natural killer cells and their receptors in multiple sclerosis. Brain (2012) 0.87

The structural basis of ligand recognition by natural killer cell receptors. J Biomed Biotechnol (2011) 0.87

Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity. Br J Cancer (2013) 0.87

The modulation of the cell-cycle: a sentinel to alert the NK cells of dangers. Front Immunol (2013) 0.86

Hunting for clinical translation with innate-like immune cells and their receptors. Leukemia (2013) 0.86

Emerging Co-signaling Networks in T Cell Immune Regulation. Immune Netw (2013) 0.86

NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol (2015) 0.85

Structural insights into activation of antiviral NK cell responses. Immunol Rev (2012) 0.85

Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Adv Virol (2011) 0.85

Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells. J Immunol (2010) 0.85

Five Layers of Receptor Signaling in γδ T-Cell Differentiation and Activation. Front Immunol (2015) 0.85

Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget (2015) 0.85

Natural killer cells and their role in rheumatoid arthritis: friend or foe? ScientificWorldJournal (2012) 0.84

B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology (2015) 0.84

B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation. Cancer Sci (2016) 0.84

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Cancer Immunol Immunother (2012) 0.83

Evasion of natural killer cells by influenza virus. J Leukoc Biol (2010) 0.83

Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy. Hum Gene Ther (2012) 0.82

NKp44 and Natural Cytotoxicity Receptors as Damage-Associated Molecular Pattern Recognition Receptors. Front Immunol (2015) 0.82

Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther (2014) 0.81

B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer. Int J Clin Exp Pathol (2015) 0.81

Monitoring NK cell activity in patients with hematological malignancies. Oncoimmunology (2013) 0.81

NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. J Immunol (2014) 0.81

B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Ther (2015) 0.81

Articles cited by this

NK cell recognition. Annu Rev Immunol (2005) 14.40

Functions of natural killer cells. Nat Immunol (2008) 9.88

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73

Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 7.07

MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol (2005) 6.98

Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 6.95

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32

New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38

Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev (2006) 3.30

Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med (1999) 3.08

The binding site for C1q on IgG. Nature (1988) 3.03

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res (2002) 3.00

A DNA microarray survey of gene expression in normal human tissues. Genome Biol (2005) 2.90

Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol (2005) 2.55

NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31

Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood (2008) 2.13

CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods (1994) 2.01

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95

Cellular ligands of activating NK receptors. Trends Immunol (2005) 1.84

Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature (1988) 1.67

Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One (2008) 1.63

Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood (2005) 1.55

Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J Neuroimmunol (2000) 1.28

Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res (2009) 1.27

Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One (2007) 1.26

Mistaken notions about natural killer cells. Nat Immunol (2008) 1.19

IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol (1999) 1.01

Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies. Arthritis Rheum (2008) 0.96

Sulfated N-linked oligosaccharides in mammalian cells. II. Identification of glycosaminoglycan-like chains attached to complex-type glycans. J Biol Chem (1988) 0.87

Articles by these authors

International network of cancer genome projects. Nature (2010) 20.35

The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci (2011) 11.79

IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22

Functions of natural killer cells. Nat Immunol (2008) 9.88

Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68

Time for a change: putting the Transtheoretical (Stages of Change) Model to rest. Addiction (2005) 8.61

Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol (2013) 7.94

Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73

TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86

An invitation to an alcohol industry lobby to help decide public funding of alcohol research and professional training: a decision that should be reversed. Addiction (2004) 5.61

Coordinate regulation of energy transduction modules in Halobacterium sp. analyzed by a global systems approach. Proc Natl Acad Sci U S A (2002) 4.96

Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry. Genome Biol (2004) 4.91

Why evidence for the fetal origins of adult disease might be a statistical artifact: the "reversal paradox" for the relation between birth weight and blood pressure in later life. Am J Epidemiol (2005) 4.81

Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol (2008) 4.78

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

Human Plasma PeptideAtlas. Proteomics (2005) 4.52

Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics (2004) 4.09

Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction (2005) 3.95

Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol (2008) 3.93

Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86

Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction (2011) 3.80

Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A (2007) 3.60

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52

Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. Addict Behav (2008) 3.52

Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43

The integrity of the science base: a test case. Addiction (2005) 3.40

Maturation of mouse NK cells is a 4-stage developmental program. Blood (2009) 3.31

Who is responsible for the public's health? The role of the alcohol industry in the WHO global strategy to reduce the harmful use of alcohol. Addiction (2013) 3.24

A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21

Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10

Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2003) 3.06

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res (2002) 3.00

CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91

Strength of urges to smoke as a measure of severity of cigarette dependence: comparison with the Fagerström Test for Nicotine Dependence and its components. Addiction (2010) 2.87

Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol (2002) 2.87

Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med (2007) 2.85

Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80

Development of a taxonomy of behaviour change techniques used in individual behavioural support for smoking cessation. Addict Behav (2010) 2.78

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75

Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction (2014) 2.73

Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A (2006) 2.72

Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol (2004) 2.65

The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64

The trafficking of natural killer cells. Immunol Rev (2007) 2.62

Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev (2009) 2.58

Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 2.55

Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44

The study of macromolecular complexes by quantitative proteomics. Nat Genet (2003) 2.44

Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res (2004) 2.34

NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31

Smoking prevalence in England is below 20% for the first time in 80 years. BMJ (2014) 2.31

The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29

Gradual Versus Abrupt Smoking Cessation: A Randomized, Controlled Noninferiority Trial. Ann Intern Med (2016) 2.24

Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol (2007) 2.24

CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21

Identification of behaviour change techniques to reduce excessive alcohol consumption. Addiction (2012) 2.21

Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology (2005) 2.21

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood (2004) 2.17

Compulsory detention, forced detoxification and enforced labour are not ethically acceptable or effective ways to treat addiction. Addiction (2012) 2.15

NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol (2009) 2.12

Germ-line and rearranged Tcrd transcription distinguish bona fide NK cells and NK-like gammadelta T cells. Eur J Immunol (2007) 2.11

Cutting edge: Priming of NK cells by IL-18. J Immunol (2008) 2.08

A software suite for the generation and comparison of peptide arrays from sets of data collected by liquid chromatography-mass spectrometry. Mol Cell Proteomics (2005) 2.08

Should smokers be offered assistance with stopping? Addiction (2010) 2.07

Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev (2008) 2.05

A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat (2010) 2.03

Moderators and mediators of a web-based computer-tailored smoking cessation program among nicotine patch users. Nicotine Tob Res (2006) 2.01

Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc Natl Acad Sci U S A (2011) 2.01

Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol (2007) 2.00

The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99

Identification of TFB5, a new component of general transcription and DNA repair factor IIH. Nat Genet (2004) 1.99

Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science (2012) 1.98

Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses. J Immunol (2011) 1.97

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood (2008) 1.96

DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95

IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol (2011) 1.94

High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry. Mol Cell Proteomics (2004) 1.94

Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog (2007) 1.93

Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92

Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem (2002) 1.89

Quantitative proteomic analysis of Myc oncoprotein function. EMBO J (2002) 1.89